Flexion Therapeutics, Inc.

Panmira Pharmaceuticals, LLC

Amira Pharmaceuticals, Inc.

Intarcia Therapeutics, Inc.

Biotie Therapies Corporation

Mark Moran

John Howard Hutchinson

Robert C Blanks

Petpiboon Peppi Prasit

Jillian Frances Evans

Neil Bodick

Anjali Kumar

Michael D Clayman

Nicholas Simon Stock

Jasmine Eleanor Zunic

Jeannie M Arruda

Yiwei Li

Brian Andrew Stearns

Mustapha Haddach

Jeffrey Roger Roppe

Lesley Pickford

Tom Woiwode

Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Corticosteroids for the treatment of joint pain

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.

Methods for treating dependence

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

5-lipoxygenase-activating protein (FLAP) inhibitors

A method for treating a human comprises administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

5-lipdxygenase-activating protein (FLAP) inhibitors

Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained release delivery system that is suitable for long-term administration. A principal advantage of the method is that responsiveness to treatment can be ascertained with short-term dosimetric techniques using one formulation of an interferon, which permits the appropriate selection of a dose that is both effective and safe for long-term administration using the second formulation.

Method for treating hepatitis C virus with omega interferon

Growing community of inventors

Orinda, CA, United States of America

Mark Moran